

AMGN - Old is Gold = Value Buy!

<https://marketpublishers.com/r/AB735417E42EN.html>

Date: November 2011

Pages: 4

Price: US\$ 140.00 (Single User License)

ID: AB735417E42EN

Abstracts

Robust cash (total cash: \$17.6b, Lt. Debt: \$20.2b) and attractive valuations along with dividend payout and philosophy to pursue “innovation” in a balanced way should keep shareholders interested in AMGN for long term. PhIII data from study ‘147 published in The Lancet found that XGEVA significantly prolonged bone metastasis-free survival, delayed time to bone metastasis and reduced the risk of symptomatic bone metastases. Based on the data, we are optimistic about its approval in... Restructuring in R&D – reduction in headcount and discontinued two PhII programs – Conatumumab (AMG 655) for various cancers and AMG 827 for Crohn’s disease. Operating margins will improve from... For more detail, please read our report released on 25th November on AMGN titled “AMGN - Old is Gold = Value Buy!”

Contents

COMPANIES MENTIONED

AMGEN

I would like to order

Product name: AMGN - Old is Gold = Value Buy!

Product link: <https://marketpublishers.com/r/AB735417E42EN.html>

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AB735417E42EN.html>